Tag Archives: After

Ionis’ Tegsedi gets a U.K. boost after NICE reverses initial guidance

The path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from England’s drug-price watchdog. Fortunately for the drugmaker, that decision was reversed. Tuesday, the National Institute for Health and Care Excellence (NICE) released (PDF) final guidance recommending Tegsedi’s placement on England’s National Health Service for treatment of nerve damage from… Read More »

After Apotex founder’s murder, family weighs sale worth up to $3B: report

The family in control of Canadian generics maker Apotex is weighing a sale, Bloomberg reports. (Pixabay) It’s been a tumultuous year and a half at Canadian generics maker Apotex, and now the company is weighing a sale, Bloomberg reports. The development comes after Apotex’s late founder Barry Sherman and his wife Honey were found murdered… Read More »